Posted by Michael Wonder on 09 Sep 2019
FDA grants AMG 510 fast track designation for previously treated metastatic NSCLC with KRAS G12C mutation
8 September 2019 - Amgen today announced new data from the ongoing Phase 1 study evaluating AMG 510 in patients with previously treated KRAS G12C-mutated solid tumours.
AMG 510 is a first-in-class investigational oral therapy that is designed to selectively and irreversibly target the KRASG12C protein.
The additional follow-up in a larger group of patients with non-small cell lung cancer (NSCLC) continued to show anti-tumour activity with no dose-limiting toxicities.
These data are being presented during an oral presentation at IASLC 2019 World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer.
